Search

In a new study, MSK researchers looked at why glioblastoma brain tumors usually come back after treatment. Their findings suggest that a subset of cells — cancer stem cells — are able to evade current treatments because they are not actively dividing, and that these cells later form new tumors.

… Tuesday, January 11, 2022 Glioblastoma brain tumors are one of the most deadly forms of cancer, with a five-year survival rate of less than 10% for patients 45 and older. Even when the tumors look as if they have been fully removed, they almost always come back. Investigators who are part of Memorial

MSK studies presented at the 2022 American Association for Cancer Research meeting include updates on a targeted therapy for lung cancer, lab research on combining statins with a breast cancer drug, and a new tool for diagnosing blood cancer.

… Monday, April 11, 2022 Dozens of investigators from Memorial Sloan Kettering Cancer Center (MSK) shared their research at the 2022 American Association for Cancer Research (AACR) annual meeting, held April 8 to 13 in New Orleans. The studies presented included: A clinical trial that looked at the long-term

Collaboration will enhance innovation and the adoption of AI in translational research with the goal of improving patient care and outcomes.

… Monday, February 17, 2025 Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN) and Memorial Sloan Kettering Cancer Center (MSK), a leading global cancer center, today announced a collaboration harnessing the power of artificial intelligence (AI), high performance computing (HPC), and

New MSK research identifies a gene mutation associated with resistance to breast cancer treatment; reports encouraging results for expanding use of a new prostate cancer radiotherapy; determines the best radiation level for avoiding complications treating spinal tumors; and finds that proton therapy is effective against previously treated head and neck cancers.

… Tuesday, October 15, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) identifies a gene mutation associated with resistance to breast cancer treatment, as well as a possible strategy for overcoming the resistance; reports encouraging results for expanding use of a new prostate cancer

New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.

… Thursday, March 9, 2023 New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — a hub for basic science and translational research within MSK — offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial

Learn how to keep your immune system balanced.

… Wednesday, December 22, 2021 You may have read articles or seen products that claim to “boost” your immune system. But what does that mean — and is it even the right goal? Contrary to popular belief, our bodies don’t have one singular immune system. The immune system is actually made up of many different

In 2024, the MSK Giving community raised $511 million to advance MSK’s mission of ending cancer for life — every single dollar donated is making a real difference in the way we treat and understand cancer.

… Friday, June 6, 2025 In 2024, we invited the MSK Giving community to join an ambitious effort to raise $6 billion by 2030 and shape the future of cancer care — The MSK Campaign: Leading Science. Changing Lives .  In response, MSK donors contributed $511 million to advance MSK’s mission of ending cancer

Developmental biologist Maria Jasin studies homologous recombination, which is important in DNA repair and can lead to cancer when it malfunctions.

… Friday, July 1, 2011 Summary Developmental biologist Maria Jasin studies homologous recombination, which is important in DNA repair and can lead to cancer when it malfunctions. When chromosomes are copied and divided faithfully and no DNA damage is passed on, a parent cell gives rise to two identical

Androgen-deprivation therapy, a mainstay of prostate cancer treatment, may give prostate cells new growth abilities, scientists at Memorial Sloan Kettering have found.

… Thursday, April 30, 2020 Summary The prostate gland has a remarkable ability to regrow itself after hormone-deprivation therapy. A new study from researchers at Memorial Sloan Kettering explains why. The standard treatment for men with advanced prostate cancer is androgen-deprivation therapy. Androgens

A new imaging technology developed at MSK allows researchers to focus on genes as they are copied into messenger RNA.

… Friday, July 5, 2019 Summary For the first time, SKI investigators have found a way to peer inside living cells and observe gene transcription, the process by which DNA is copied into messenger RNA. A picture is worth a thousand words, or so the saying goes. But it can be quite a challenge to capture